College of Pharmacy, Jinan University, Guangzhou 510632, P. R. China.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
J Med Chem. 2022 Jan 13;65(1):688-709. doi: 10.1021/acs.jmedchem.1c01781. Epub 2021 Dec 24.
Development of new bacterial biofilm inhibitors as antibacterial synergists is an effective strategy to solve the resistance of . In this paper, a series of 3-hydroxy-pyridin-4(1)-ones were synthesized and evaluated, and the hit compound () was identified with the effects of inhibiting the production of pyocyanin (IC = 8.6 μM) and biofilm formation (IC = 4.5 μM). Mechanistic studies confirmed that inhibits the formation of bacterial biofilm by inhibiting the expression of , blocking quorum sensing system quinolone biosynthesis. Moreover, we systematically investigated the bactericidal effects of combining currently approved antibiotics for CF including tobramycin, ciprofloxacin, and colistin E with , which showed obvious antibacterial synergy to overcome antibiotics resistance in multidrug-resistant biofilms. The result indicates that compound may be used in the future as a potentially novel antibacterial synergist candidate for the treatment of infections.
开发新型细菌生物膜抑制剂作为抗菌增效剂是解决耐药性的有效策略。在本文中,我们合成了一系列 3-羟基-4(1H)-吡啶酮,并对其进行了评价,发现具有抑制绿脓菌素产生(IC = 8.6 μM)和生物膜形成(IC = 4.5 μM)作用的先导化合物 ()。机制研究证实,通过抑制 的表达,抑制细菌生物膜的形成,阻断群体感应系统喹诺酮生物合成。此外,我们系统地研究了将目前批准用于 CF 的抗生素(包括妥布霉素、环丙沙星和多粘菌素 E)与 联合使用的杀菌效果,结果显示对克服多药耐药生物膜中的抗生素耐药性具有明显的抗菌协同作用。结果表明,化合物 可能在未来作为一种有潜力的新型抗菌增效剂候选药物,用于治疗 感染。